A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain
Public ClinicalTrials.gov record NCT05359133. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To be eligible for the trial, subjects must have ongoing moderate to severe neuropathic pain related to a prior course of platinum and/or taxane chemotherapy and have no clinical evidence of actively progressive disease. The trial period will comprise a Screening period (up to 35 Days), randomization and a 4-day treatment period, followed by a 12-week follow up period (12 weeks total after initial treatment), and an End-of-Trial/Follow-up visit which will occur at Week 13. This is a study to research the effects of the study drug on neuropathic pain compared placebo.
Study identification
- NCT ID
- NCT05359133
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 35 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 21 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 19, 2022 (Actual)
- Primary completion
- Oct 14, 2024 (Actual)
- Completion
- Oct 14, 2024 (Actual)
- Last update posted
- Feb 20, 2025
2022 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Syrentis Clinical Research | Santa Ana | California | 92705 | — |
| Providence Medical Foundation | Santa Rosa | California | 95403 | — |
| MEDSOL Clinical Research Center | Port Charlotte | Florida | 33952 | — |
| Care Access Research | Macon | Georgia | 31201 | — |
| Paradigm Clinical Research | Boise | Idaho | 83709 | — |
| Clinical Trials of SWLA | Lake Charles | Louisiana | 70601 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| St Luke's Hospital of Kansas City | Kansas City | Missouri | 64111 | — |
| Care Access Research | Clifton | New Jersey | 07013 | — |
| ES Clinical Research Group | Garden City | New York | 11530 | — |
| SUNY Upstate Medical University | Syracuse | New York | 13210 | — |
| Oncology Specialists of Charlotte | Charlotte | North Carolina | 28207 | — |
| Oklahoma Cancer Specialists and Research Institute (OCSRI) | Tulsa | Oklahoma | 74146 | — |
| Center for Oncology and Blood Disorders (COBD) | Houston | Texas | 77030 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05359133, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2025 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05359133 live on ClinicalTrials.gov.